Navigation Links
Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions

EXETER, N.H.--(BUSINESS WIRE)--May 24, 2007 - Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, today announced that a late breaking abstract sponsored by the Company has been accepted for a poster presentation at the American Diabetes Association 67th Scientific Sessions in Chicago. The abstract, entitled "Results of a Randomized, Single-Dose, 2/3-Way Crossover Comparison Study of Intranasal Insulin Spray (Nasulin(TM)) and Injectable Fast-Acting Insulin (Humalog(R)) in Normal Nonsmoking and Smoking Subjects," will be included in the category of Clinical Therapeutics/New Technology - Insulin Delivery Systems and displayed Saturday, Sunday and Monday, June 23-25, 2007, in the General Poster Session in the Exhibit Hall.

As previously announced, Bentley had two other abstracts accepted, one for oral presentation and another for a poster presentation. The abstract on "Interim Results of a Randomized, Single-Dose, 4-Way Crossover, Pharmacokinetic Study of Intranasal Insulin Spray (Nasulin(TM)), Injectable Regular Insulin (Humulin R(R)), Injectable Fast-Acting Insulin (Humalog(R)), and Saline Nasal Spray in Patients with Type I Diabetes Mellitus," has been selected for oral presentation by Dr. Sherwyn L. Schwartz, M.D., of dgd Research, Inc., as part of the first session on Friday, June 22, 2007. In addition, the abstract, "Intranasal Insulin Spray (Nasulin(TM)) in Healthy Subjects: Choice of Nostril," will also be displayed Saturday through Monday, June 23-25, 2007, in the General Poster Session in the Exhibit Hall.

Founded in 1979 by Dr. Schwartz, the Diabetes & Glandular Disease Clinic is the largest private endocrine clinic in the United States with over 70,000 active patients, eight board certified endocrinologists, seven NPs/PAs and an ADA recognized diabetes education program. The research arm, dgd Research Associates, Inc., has a staff of over 250 employees and has cond ucted over 1,500 Phase I through III clinical trials, primarily in targeted endocrine populations. Currently work is underway on construction of a new 80,000sq. ft. Phase I unit. For more information visit www.dgdclinic.com and www.dgdresearch.com.

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and generic pharmaceutical products. Bentley's proprietary drug delivery technologies enhance the absorption of pharmaceutical compounds across various membranes. Bentley manufactures and markets a growing portfolio of generic and branded generic pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and central nervous system diseases through its subsidiaries -- Laboratorios Belmac, Laboratorios Davur, Laboratorios Rimafar and Bentley Pharmaceuticals Ireland. Bentley also manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API.

Additional information regarding Bentley Pharmaceuticals may be obtained through Bentley's web site at www.bentleypharm.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward looking statements, including without limitation, statements regarding plans for the announcement of interim results of clinical trials of Bentley's intranasal insulin product candidate. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, risks associated with the efficacy and safety of Bentley's intranasal insulin product candidate and its drug delivery technology, risks associated with international clinical trials, and other risks detailed under Item 1A "Risk Factors" in Bentley's most recent Annual Report on Form 10-K and its subseq uent periodic reports filed with the Securities and Exchange Commission. Bentley cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Bentley undertakes no obligation to update or revise the statements, except as may be required by law.

Contact

Bentley Pharmaceuticals, Inc.
Jean DeRoche, 603-658-6136
jderoche@bentleypharm.com
or
Sharon Merrill Associates
Jim Buckley, 617-542-5300
bnt@investorrelations.com


'"/>




Related medicine technology :

1. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
4. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
5. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
6. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
7. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
8. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
9. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
10. OXiGENE Abstracts Published in ASCO Program
11. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Los innovadores de COMBO[TM], ... introduce catéteres para la intervención de extremidades inferiores ... global especializada en el suministro de soluciones vasculares ... incluyendo productos para tratar la enfermedad arterial periférica. ... los dispositivos de primera entrada de la compañía ...
(Date:5/24/2016)... , May 24, 2016 ... elkaar verbindt, zodat zij collectief patiënten kunnen behandelen, hun ... is het idee achter de nieuwe en revolutionaire MDLinking ... van de Nederlandse vaatchirurg dr. Hans Flu en oncologisch ... app, die inmiddels beschikbaar is, wordt op dinsdag 24 ...
(Date:5/23/2016)... York , May 23, 2016 ... report titled, " Exocrine Pancreatic Insufficiency Market - Global ... - 2023 ." According to the report, the exocrine ... CAGR of 8.3% from 2015 to 2023 to reach ... (EPI) is a condition characterized by the deficiency of ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... The ... Drug Development through Molecular Imaging.” The focus of ADDMI-IG will be geared towards ... and development pipeline issues. Through ADDMI-IG WMIS will provide a platform for productive ...
(Date:5/25/2016)... Miami, FL (PRWEB) , ... May 25, 2016 , ... ... deep dive into the unique integrative medical wellness offerings of Europe, a continent that ... in Tyrol, Austria will hear from numerous pioneers in medical wellness, including Henri Chenot, ...
(Date:5/25/2016)... ... ... Casa Velas, an adults-only boutique hotel in Puerto Vallarta, Mexico, introduces a ... wellness suites . The two 1,350 sq. ft. suites which debuted in late 2015 ... amenities, from a custom soap selection and in-suite exercise kit to a personal wellness ...
(Date:5/25/2016)... ... May 25, 2016 , ... America Walks , a ... M.S.L., M.S.P.A., of the University of Pittsburgh Graduate School of Public Health , ... Ms. Reichbaum and 24 other advocates from around the country to participate in a ...
(Date:5/25/2016)... ... May 25, 2016 , ... "FCPX LUT Intense allows users to ... said Christina Austin - CEO of Pixel Film Studios. , With the FCPX ... add stylish color grades to their footage. A LUT is a Lookup Table that ...
Breaking Medicine News(10 mins):